HUMA
Humacyte, Inc. News
Sign up for free!
Get instant access to all of our market news and analysis with our free REST API.
Latest news
Live response for past 24 hours
{
"meta": {
"found": 2,
"returned": 2,
"limit": 10,
"page": 1
},
"data": [
{
"uuid": "7ba47f88-bf3c-4930-8a3b-2a97557f452e",
"title": "Humacyte stock gains amid ongoing FDA review (NASDAQ:HUMA)",
"description": "Humacyte (HUMA) stock continues to rise as analysts comment on an ongoing FDA review of its bioengineered blood vessel product, HAV. Read more here.",
"keywords": "",
"snippet": "Following a ~17% gain in the previous session, Humacyte (NASDAQ:HUMA) shares continued to trade higher in the premarket Tuesday amid an ongoing FDA review of th...",
"url": "https://seekingalpha.com/news/4105703-humacyte-stock-gains-amid-ongoing-fda-review",
"image_url": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1293101930/image_1293101930.jpg?io=getty-c-w750",
"language": "en",
"published_at": "2024-05-14T11:28:38.000000Z",
"source": "seekingalpha.com",
"relevance_score": null,
"entities": [
{
"symbol": "HUMA",
"name": "Humacyte, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "N/A",
"match_score": 113.32829,
"sentiment_score": 0.36948,
"highlights": [
{
"highlight": "Following a ~17% gain in the previous session, <em>Humacyte</em> (<em>NASDAQ:HUMA</em>) shares continued to trade higher in the premarket Tuesday amid an ongoing FDA review of the company’s marketing application for its experimental bioengineered blood vessel, Human Acellular Vessel (HAV).",
"sentiment": 0.6808,
"highlighted_in": "main_text"
},
{
"highlight": "The U.S. regulator accepted Humacyte’s (<em>HUMA</em>) biologics license application for HAV early this year to review it for vascular trauma indication, with a target action date of August 10, 2024.",
"sentiment": -0.1779,
"highlighted_in": "main_text"
},
{
"highlight": "“We expect investor interest in <em>HUMA</em> to continue to grow as the company approaches these landmark milestones later this year,” he added in a note last Friday.",
"sentiment": 0.5106,
"highlighted_in": "main_text"
},
{
"highlight": "Meanwhile, citing remarks from Humacyte’s (<em>HUMA</em>) management, Benchmark analyst Bruce Jackson, who has a Buy rating and a $15 per share target on <em>HUMA</em>, said that the company has the potential to reach a global market worth more than $90B across four indications.",
"sentiment": 0.4939,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Humacyte</em> stock gains amid ongoing FDA review (<em>NASDAQ:HUMA</em>)",
"sentiment": 0.34,
"highlighted_in": "title"
}
]
}
],
"similar": []
},
{
"uuid": "41189d3f-9b7c-4337-91c9-773ea6598a1d",
"title": "Earnings call: Humacyte anticipates strong market entry post-FDA review By Investing.com",
"description": "Earnings call: Humacyte anticipates strong market entry post-FDA review",
"keywords": "",
"snippet": "Humacyte, Inc. (HUMA), a biotechnology company specializing in regenerative medicine, has recently announced its financial results for the first quarter of 2024...",
"url": "https://www.investing.com/news/stock-market-news/earnings-call-humacyte-anticipates-strong-market-entry-postfda-review-93CH-3437670",
"image_url": "https://i-invdn-com.investing.com/news/LYNXNPEC0D0AP_L.jpg",
"language": "en",
"published_at": "2024-05-13T16:50:52.000000Z",
"source": "investing.com",
"relevance_score": null,
"entities": [
{
"symbol": "HUMA",
"name": "Humacyte, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "N/A",
"match_score": 51.09768,
"sentiment_score": 0.423891,
"highlights": [
{
"highlight": "<em>Humacyte</em>, <em>Inc</em>. (<em>HUMA</em>), a biotechnology company specializing in regenerative medicine, has recently announced its financial results for the first quarter of 2024, alongside providing a business update that indicates a significant stride towards the commercial launch of its flagship product, the <em>Humacyte</em> Vascular Access Graft (HAV).\n\nThe U.S.",
"sentiment": 0.296,
"highlighted_in": "main_text"
},
{
"highlight": "See disclosureor\n\nInvestingPro Insights\n\n<em>Humacyte</em>, <em>Inc</em>. (<em>HUMA</em>) presents a compelling case for investors as it makes significant strides towards the launch of its <em>Humacyte</em> Vascular Access Graft (HAV). With the FDA's Priority Review status, the company's operational focus is clear.",
"sentiment": 0.6486,
"highlighted_in": "main_text"
},
{
"highlight": "However, a closer look at the financial health and market performance of <em>Humacyte</em> through InvestingPro insights reveals several critical points that investors should consider.",
"sentiment": -0.3182,
"highlighted_in": "main_text"
},
{
"highlight": "Use coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription, and gain access to the full suite of InvestingPro Tips, which currently lists a total of 14 tips for <em>HUMA</em> at https://www.investing.com/pro/<em>HUMA</em>.",
"sentiment": 0.5267,
"highlighted_in": "main_text"
},
{
"highlight": "These tips and metrics can be invaluable for making informed investment decisions as <em>Humacyte</em> continues on its path towards commercialization.\n\nFull transcript - Alpha Healthcare Acquisition (<em>HUMA</em>) Q1 2024:\n\nOperator: Good morning, ladies and gentlemen, and welcome to the <em>Humacyte</em> First Quarter 2024 Results Conference Call.",
"sentiment": 0.7096,
"highlighted_in": "main_text"
},
{
"highlight": "Information presented on this call is contained in the press release we issued this morning and on our Form 10-Q, which, after filing, may be accessible from the Investor page of the <em>Humacyte</em> website. Joining me on today's call from <em>Humacyte</em> are Dr.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "The entire <em>Humacyte</em> team has been actively engaged in commercial readiness activities to support our anticipated U.S. market launch.",
"sentiment": 0.8271,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Humacyte</em> is pleased to announce that we've hired Morgan Rankin as Vice President of Sales, joining <em>Humacyte</em> after 12 years at Teleflex (NYSE: ) Medical.",
"sentiment": 0.4404,
"highlighted_in": "main_text"
},
{
"highlight": "This is a very exciting time for <em>Humacyte</em> and for all of our stakeholders. I'd like to take a moment again to thank the <em>Humacyte</em> team as well as all of our partners for their continued commitment to our programs. Our team's dedication has been instrumental in reaching this crucial and exciting stage in our company's development.",
"sentiment": 0.9448,
"highlighted_in": "main_text"
},
{
"highlight": "You did talk about ICD-10s for <em>Humacyte</em> -- for the HAV, excuse me.",
"sentiment": 0.0772,
"highlighted_in": "main_text"
},
{
"highlight": "Earnings call: <em>Humacyte</em> anticipates strong market entry post-FDA review By Investing.com",
"sentiment": 0.5106,
"highlighted_in": "title"
}
]
}
],
"similar": []
}
]
}
Sentiment
Live response for past 24 hours
{
"meta": {
"returned": 1,
"limit": 10
},
"data": [
{
"key": "HUMA",
"total_documents": 2,
"sentiment_avg": 0.39668551087379456
}
]
}
Other details
Exchange
- NASDAQ Stock Exchange
- equity
- N/A
- us